A market report published from Dublin details advanced molecular diagnostics and key players in the hemato-oncology testing market.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A market report published from Dublin details advanced molecular diagnostics and key players in the hemato-oncology testing market.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Also in this story
- Skyclarys announced its international expansion into Brazil and the U.K. on July 22, 2025.
- Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.
- Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.
- Sooin was appointed Chief Business and Strategy Officer at Galapagos, which also announced a partnership with Gilead.
The entities involved
-
Pacific Biosciences
biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation
Nothing else this week.
-
Hoffmann-La Roche
Swiss healthcare company
-
Qiagen
company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireHemato-Oncology Testing Market Size, Share & Trends Analysis Report 2025-2030 Featuring Key Players Roche, Abbott, EntroGen, Qiagen, and Cepheid (Danaher) Among Others Opportunities in the hemato-onc